News

  • Leigh Burgess, MHA, MEd, MA, vice president of research operations for Dartmouth-Hitchcock Health, couldn’t wait to get back to her office after COVID-19 safety precautions forced her and most of her team to work remotely back in March. Burgess has been able to work full-time onsite since mid-May, and says her facility has done a…
  • Alarming economic news continues to pummel the clinical trial industry as more and more trials are stalled or even scrapped while industry tries to navigate its way through the COVID-19 pandemic. Earlier this month, an ongoing quantitative survey conducted by Continuum Clinical in partnership with the Association of Clinical Research Professionals (ACRP) found 31% of clinical research study sites…
  • With the recent development of the current Covid-19 pandemic, there has been an increased urgency for both industry and non-industry sponsors to focus on finding a suitable therapeutic or vaccine for this highly contagious viral disease. In an effort to find a suitable treatment and prevention options for Covid-19 infection, more Covid-19 clinical trials are…
  • The world's leading drug companies, universities and governments are racing to develop a vaccine for COVID-19, the disease that has taken more than 400,000 lives globally. Of the 133 candidates being explored, ten have been approved for human trials, according to the World Health Organization. Companies and research groups in China, the early epicenter of the coronavirus outbreak, are testing five…
  • Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals The COVID-19 pandemic has created an urgent need for scientific solutions to this deadly virus. The pandemic surprised the world with a new strain of coronavirus never encountered before, which, like its predecessor, has the capacity to infect humans with severe and deadly consequences. While…
  • You get one chance to initiate a clinical trial. Botch the start-up and you’ll expend great effort correcting course and playing catch-up. The waste of money and time — commodities that are chronically scarce among the biotech and specialty pharma companies that comprise most of our customer base — can be devastating. That’s why we…
  • Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, announced that it has received FDA permission to initiate a Phase 2 clinical trial to assess the efficacy of VERU-111, a microtubule depolymerization agent, in combating COVID-19, the global pandemic disease caused…
  • Emory University and Eli Lilly have developed a strategy for studying the safety and efficacy of an anti-inflammatory drug baricitinib as a potential treatment for patients hospitalized with COVID-19. The National Institute of Allergy and Infectious Diseases (NIAID) announced Friday it has agreed to evaluate a treatment regimen of the investigational antiviral remdesivir, plus the…
  • As scientists around the world race to develop a vaccine for COVID-19, researchers at Oxford University have now pulled into the lead. The team recently began testing a vaccine candidate in people that—if effective—could possibly become available as early as September, the New York Times reported on April 27. That would be well before any other vaccine effort…
  • The coronavirus disease 2019 (COVID-19) pandemic will lead to increasing adoption of artificial intelligence, automation, and virtual clinical trials, according to a prediction presented Thursday, during a virtual session of the Community Oncology Alliance 2020 Meeting. “We really are in a place now to not lose momentum as we go through the pandemic, but in…